[]
投稿者：[]
投稿日：[Zoya Demidenko: Researcher in Cancer Studies
Zoya Demidenko is a prominent investigator connected with the Department of Cell Stress Science at Roswell Park Oncology Institute in Buffalo, New York. Earlier, she conducted research at the National Institutes of Health and New York Medical College, developing a strong base in clinical study.
Demidenko's scholarly work covers a number of key fields, including the PI3K/AKT/mTOR molecular pathway, cellular cycle management, biological aging, and cancer biology. Currently, she has co-authored more than 46 peer-reviewed papers, which have received over 4,100 citations a indicator to the significance of her work.
One of her key discoveries lies in explaining the mechanisms of cell aging. Her research showed that when the cellular division cycle is halted but cellular growth persists, the cells enter senescence. Crucially, Zoya Demidenko established that this process can be inhibited by medication using compounds such as rapamycin.
Zoya Demidenko has also brought considerably to oncological therapy research, especially in the area of cyclotherapy a approach intended to safeguarding normal tissue from chemotherapy whilst leaving malignant cells susceptible. This strategy offers significant potential for diminishing the toxic effects of cancer treatment.
Across her career, Demidenko has collaborated with prominent researchers worldwide, such as Dr. Mikhail Blagosklonny. Her research appears in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko stands as a widely cited figure in current cancer research, with her results continue to influence our knowledge of how biological cells age, interact with therapy, and the ways in which malignant disease might be more successfully targeted.
https://www.instagram.com/hibou_sova/
]
|
|
|